PAI and TPA gene polymorphisms in multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 243-247

  Lovrečić, Luca ^a   Ristić, Smiljana ^b   Starčević Čizmarević, Nada ^b   Brajenović Milic, Bojana ^b   Jazbec, Saša Sega ^a   Sepčić, Juraj ^b   Kapović, Miljenko ^b   Peterlin, Borut ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

gene polymorphism; multiple sclerosis; PAI 4G 5G; susceptibility gene; TPA Alu I D

Indexed keywords

INITIATION FACTOR; INITIATION FACTOR 4G; INITIATION FACTOR 5G; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROMOTER REGION;

ADOLESCENT; ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 43149126375     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507082603     Document Type: Article

References (18)

1. Compston A., Coles A. Multiple sclerosis. The Lancet 2002; 359 (6): 1221-31.
2. Martinez Doncel A, Rubio A., Arroyo R., de las Heras V., Martin C., Fernandez-Arquero M., et al. Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J Neuroimmunol 2002; 131 (1-2): 168-72.
3. Gveric D., Hanemaaijer R., Newcombe J., van Lent NA, Sier CF, Cuzner ML Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 2001; 124: 1978-88.
4. Gveric D., Herrera B., Petzold A., Lawrence DA, Cuzner ML Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003; 126 (Pt 7): 1590-8.
5. Gveric D., Herrera BM, Cuzner ML tPA receptors and the fibrinolytic response in multiple sclerosis lesions. Am J Pathol 2005; 166 (4): 1143-51.
6. Teesalu T., Hinkkanen AE, Vaheri A. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol 2001; 159 (6): 2227-37.
7. Eriksson P., Kallin B., van 't Hooft FM, Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92 (6): 1851-5.
8. Luomala M., Elovaara I., Ukkonen M., Koivula T., Lehtimaki T. Plasminogen activator inhibitor 1 gene and risk of MS in women. Neurology 2000; 54 (9): 1862-4.
9. Poser CM, Paty DW, Scheinberg L., McDonald WI, Davies FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
10. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33 (11): 1444-52.
11. Margaglione M., Grandone E., Cappucci G., Colaizzo D., Giuliani N., Vecchione G., et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77 (3): 605-6.
12. Jern C., Ladenvall P., Wall U., Jern S. Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA. Arterioscler. Thromb Vasc Biol 1999; 19 (2): 454-9.
13. van der Bom JG, de Knjiff P., Haverkate F., Bots ML, Meijer P., de Jong PT, et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997; 95 (12): 2623-7.
14. Hirschhorn JN, Lohmueller K., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4 (2): 45-61.
15. van den Eijnden-Schrauwen Y., Lakenberg N., Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue type plasminogen activator gene does not affect basal endothelial tPA synthesis. Thromb Haemost 1995; 74 (4): 1202.
16. Chandler WL, Levy WC, Stratton JR The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92 (10): 2984-94.
17. Chandler WL, Alessi MC, Aillaud MF, Henderson P., Vague P., Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-l) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96 (3): 761-8.
18. Ladenvall P., Nilsson S., Jood K., Rosengren A., Blomstrand C., Jern C. Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 2003; 11 (8): 603-10.